AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Valneva SE shares rise 5.42% intraday after announcing an exclusive vaccine marketing and distribution agreement with CSL Seqirus.
ByAinvest
Thursday, Jun 26, 2025 12:18 pm ET1min read
Valneva SE rose 5.42% in intraday trading, driven by the announcement of an exclusive agreement with CSL Seqirus for the marketing and distribution of Valneva's three proprietary vaccines in Germany. The agreement includes the commercialization of Valneva's single-dose chikungunya vaccine IXCHIQ from July 2025, and its Japanese Encephalitis vaccine IXIARO and cholera/ETEC1 vaccine DUKORAL from January 2026. This new partnership replaces the previous agreement with Bavarian Nordic and is set to last for three years, with minimum annual purchasing quantities and standard termination clauses.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet